Supplementary Materials

Supplementary Material for:

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

Chasity D. Andrews, Yun Lan Yueh, William R. Spreen, Leslie St. Bernard, Mar Boente-Carrera, Kristina Rodriguez, Agegnehu Gettie, Kasi Russell-Lodrigue, James Blanchard, Susan Ford, Hiroshi Mohri, Cecilia Cheng-Mayer, Zhi Hong, David D. Ho, Martin Markowitz*

*Corresponding author. E-mail: mmarkowitz{at}adarc.org

Published 14 January 2015, Sci. Transl. Med. 7, 270ra4 (2015)
DOI: 10.1126/scitranslmed.3010298

This PDF file includes:

  • Fig. S1. Plasma PK of individual GSK744 LA–treated rhesus macaques throughout the PK study.
  • Fig. S2. Correlation of rectal tissue GSK744 concentrations by processing method before freezing.
  • Fig. S3. Correlation of cervical tissue GSK744 concentrations from individual samples.
  • Fig. S4. GSK744 plasma concentrations from Depo-Provera–treated rhesus macaques compared with humans.
  • Fig. S5. Consensus sequence analysis of SHIV integrase-coding regions from plasma of infected GSK744 LA–treated macaques.
  • Fig. S6. Minimum number of T/F variants was estimated from plasma collected within 1 week of detection of viremia.
  • Table S1. Summary of time of detection for plasma vRNA, proviral DNA, and anti-SHIV antibodies (Ab).
  • Table S2. Susceptibility of single-cycle recombinant viruses with the integrase-coding regions of SHIV162P3 viral stock, FM26, FG95, and mutants to GSK744.
  • Table S3. Env single-genome analysis summary.

[Download PDF]